| Ms Rebecca Dawn Lacasse, APRN | |
|
100 Robie Rd, Alexandria, NH 03222-6063 | |
| (603) 744-6200 | |
| Not Available |
| Full Name | Ms Rebecca Dawn Lacasse |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 100 Robie Rd, Alexandria, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841758141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 067860-23 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Sunapee Home Care & Hospice | New london, NH | Hospice |
| Entity Name | Mid-state Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235170549 PECOS PAC ID: 1951363563 Enrollment ID: O20041027000215 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
According to study results to be featured in Sunday's late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute drug-eluting stent (DES) from Medtronic, Inc. yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.
Luminex Corporation, the worldwide leader in multiplexed solutions, today announced it has donated the first commercial unit of its newly launched MAGPIX® instrument to Professor Peter Siba and his scientific team at the Papua New Guinea Institute of Medical Research. The instrument will be used onsite in Papua New Guinea to progress malaria research led by Dr. Peter Zimmerman, Professor of International Health, Genetics and Biology at the Center for Global Health and Diseases at Case Western Reserve University.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.
› Verified 5 days ago
| Entity Name | Lake Sunapee Homecare And Hospice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639564818 PECOS PAC ID: 9436114436 Enrollment ID: O20160610000214 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
According to study results to be featured in Sunday's late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute drug-eluting stent (DES) from Medtronic, Inc. yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.
Luminex Corporation, the worldwide leader in multiplexed solutions, today announced it has donated the first commercial unit of its newly launched MAGPIX® instrument to Professor Peter Siba and his scientific team at the Papua New Guinea Institute of Medical Research. The instrument will be used onsite in Papua New Guinea to progress malaria research led by Dr. Peter Zimmerman, Professor of International Health, Genetics and Biology at the Center for Global Health and Diseases at Case Western Reserve University.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Rebecca Dawn Lacasse, APRN 245 Kummerer Rd, Alexandria, NH 03222-6106 Ph: (603) 744-5153 | Ms Rebecca Dawn Lacasse, APRN 100 Robie Rd, Alexandria, NH 03222-6063 Ph: (603) 744-6200 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
According to study results to be featured in Sunday's late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute drug-eluting stent (DES) from Medtronic, Inc. yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.
Luminex Corporation, the worldwide leader in multiplexed solutions, today announced it has donated the first commercial unit of its newly launched MAGPIX® instrument to Professor Peter Siba and his scientific team at the Papua New Guinea Institute of Medical Research. The instrument will be used onsite in Papua New Guinea to progress malaria research led by Dr. Peter Zimmerman, Professor of International Health, Genetics and Biology at the Center for Global Health and Diseases at Case Western Reserve University.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.
› Verified 5 days ago